ETFs & Funds
This user currently has no profile.
Andrew Goodwin holds a Ph.D. in the cellular and molecular basis of human disease, with research experience in infectious diseases and cancer. After 11 years as an academic scientist I now work on the regulatory side of drug development. Aside from my day job, I operate the websites BiotechDueDiligence and HSP90 Central that provide in-depth, reliable information and education for biotech investors and other readers. I have also contributed to Chimera Research Group, a publisher of subscription-based biopharmaceutical insight. In 2012 I was honored to be named one of the "Top 50 Industry Voices in Biotech" by FierceBiotech and Appeering. Visit my BiotechDueDiligence website for additional bio details.
Independent / boutique research firm analyst.
ETFs, Retirement savings, Stocks - long
BiotechDueDiligence is a website dedicated to making you a better biotech investor. Biotechnology is a fascinating stock market sector that most individual investors are both intrigued by and deathly afraid of. The key to success is, like most things, doing your homework. You will find links and resources to
understand the most critical issues affecting the biopharmaceutical industry and individual companies, as well as to learn how to evaluate drug candidates from the lab bench through commercialization - not to mention the financial aspects of the biotech business and the management executives that run the companies. Not a biotech stock investor? You'll still find content here on the site that we hope will be useful to anyone with an interest in the biopharma industry. Our readers include patients, caregivers, physicians, researchers, journalists, and more. In addition to the general educational content described above, BiotechDueDiligence is also a free source of in-depth information on select small- to mid-cap biotechnology and pharmaceutical companies. However, please understand that this site does not recommend that any individual or fund buy or sell a particular stock.
BiotechDueDiligence (www.biotechduediligence.com) is your source for In-depth research notes on select small- and mid-cap biotechnology/pharmaceutical companies. The site covers basic science, clinical trials, regulatory progress, partnering, business development, mergers and acquisitions, commericalization,
and intellectual property. HSP90 Inhibitors Central (www.hsp90central.com) is a site dedicated to the class of drug inhibiting heat shock protein 90 (HSP90), a promising but historically challenging target for cancer.
Currently, there are no book details for bioduediligence.
I am not following this par...
Thoughts On The Celgene Revlimid Markman Hearing
Correct, the "human fe...
Senomyx - Addressing Each Bearish Claim
Jim, thanks for citing HSP9...
Investing In The Future Of Cancer Therapy: Synt...
Two notes / corrections:The...
Put A Royalty Legend In Your Portfolio With Lig...
First payment is next month...
Thumbs Down To Amarin's ANCHOR Would Sink Its Ship
Updates On Ariad's AP26113 ALK/EGFR Inhibitor
8 Possible Explanations For BioSante Pharma's 56% Pop
BioSante Pharma $BPAX 1q-2012 Updates
Will Amarin's AMR101 receive New Chemical Entity exclusivity from the FDA ($AMRN)
Four Beaten-down Biotech Stocks that are on my BUY list